A GP guide to SGLT2 inhibitors in type 2 diabetes

The benefits and adverse effects of this new class of medications

Need to know:

  • Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a new drug class for the treatment of type 2 diabetes that inhibit reabsorption of glucose in the renal proximal tubule to promote glycosuria and improve blood glucose levels.